Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries.

IF 4.3 2区医学 Q2 ONCOLOGY Therapeutic Advances in Medical Oncology Pub Date : 2025-01-03 eCollection Date: 2025-01-01 DOI:10.1177/17588359241299324

Bazarbashi Shouki, Alnajjar Abdelsalam, Al Sharm Abdullah, Alshammari Kanan, Al Sherhi Ahmed, Dawoud Emad, Heinemann Volker, Aseafan Mohamed, Chehal Aref, Alghamdi Mohammed, Hamza Dina, Khoury Maroun, Venniyoor Ajit, Mahrous Mervat, Rasul Kakil, Elsamany Shereef, Trad Diaeddine

{"title":"Management of metastatic colorectal cancer: consensus in the Gulf Cooperation Council countries.","authors":"Bazarbashi Shouki, Alnajjar Abdelsalam, Al Sharm Abdullah, Alshammari Kanan, Al Sherhi Ahmed, Dawoud Emad, Heinemann Volker, Aseafan Mohamed, Chehal Aref, Alghamdi Mohammed, Hamza Dina, Khoury Maroun, Venniyoor Ajit, Mahrous Mervat, Rasul Kakil, Elsamany Shereef, Trad Diaeddine","doi":"10.1177/17588359241299324","DOIUrl":null,"url":null,"abstract":"<p><p>Colorectal cancer (CRC) represents a major public health challenge globally, particularly in the Gulf Cooperation Council (GCC) countries, where it is identified as the second most prevalent form of cancer. Despite advancements in management strategies, tailored guidelines specific to the Gulf region are lacking. This paper presents consensus recommendations developed by a panel of experts from the GCC countries to address this gap. The guidelines cover epidemiology, screening, biomarkers, and treatment strategies for metastatic CRC. Treatment guidelines emphasize tailored approaches based on tumor characteristics, including sidedness and molecular profiles. Furthermore, the importance of maintenance therapy and emerging biomarkers are discussed. These guidelines aim to improve CRC management and outcomes in the Gulf region.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359241299324"},"PeriodicalIF":4.3000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11700394/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241299324","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) represents a major public health challenge globally, particularly in the Gulf Cooperation Council (GCC) countries, where it is identified as the second most prevalent form of cancer. Despite advancements in management strategies, tailored guidelines specific to the Gulf region are lacking. This paper presents consensus recommendations developed by a panel of experts from the GCC countries to address this gap. The guidelines cover epidemiology, screening, biomarkers, and treatment strategies for metastatic CRC. Treatment guidelines emphasize tailored approaches based on tumor characteristics, including sidedness and molecular profiles. Furthermore, the importance of maintenance therapy and emerging biomarkers are discussed. These guidelines aim to improve CRC management and outcomes in the Gulf region.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

转移性结直肠癌的管理：海湾合作委员会国家的共识。

结直肠癌（CRC）是全球，特别是海湾合作委员会（GCC）国家面临的一项重大公共卫生挑战，在这些国家，结直肠癌被确定为第二大最普遍的癌症形式。尽管管理战略取得了进展，但缺乏针对海湾地区的量身定制的指导方针。本文提出了由海湾合作委员会国家专家小组为解决这一差距而提出的共识性建议。该指南涵盖了转移性结直肠癌的流行病学、筛查、生物标志物和治疗策略。治疗指南强调基于肿瘤特征的量身定制的方法，包括侧边性和分子特征。此外，还讨论了维持治疗和新兴生物标志物的重要性。这些指南旨在改善海湾地区的CRC管理和结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Therapeutic Advances in Medical Oncology ONCOLOGY-

CiteScore

8.20

自引率

2.00%

发文量

160

审稿时长

15 weeks

期刊介绍： Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).